Search Medical Condition
Please enter condition
Please choose location from dropdown

Bradenton, Florida Clinical Trials

A listing of Bradenton, Florida clinical trials actively recruiting patient volunteers.

Found (162) clinical trials

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

BT5528 consists of a bicyclic peptide (Bicycle) which binds to EphA2, and is covalently attached to a spacer and a protease cleavable peptide linker attached to MMAE. The Phase I/II multi-center, open-label trial will evaluate BT5528 administered once-weekly as a single agent and in combination with nivolumab. The Phase I …

Phase

5.43 miles

Learn More »

Safety Dose Tolerance Pharmacokinetics and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

The study will initially employ an accelerated escalation design, with a single patient enrolled in each cohort (i.e., Single-Patient Cohorts). The initial patient will receive CPX-POM at a starting dose of 30 mg/m2. Doses will be escalated (doubling), until a Grade 2 toxicity (with the exception of alopecia), is encountered. …

Phase

5.43 miles

Learn More »

Phase 1b/2 Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer

This a multicenter open-label study comparing safety, tolerability and efficacy of rivoceranib monotherapy, trifluridine/tipiracil monotherapy and the combination of rivoceranib plus trifluridine/tipiracil in subjects with mCRC. Subjects with histologically or cytologically definitive adenocarcinoma of the colon or rectum who have progressed following standard of care therapy for colorectal cancer will …

Phase

5.43 miles

Learn More »

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

CONSORTIUM-IO is a first-in-human multicenter, open-label study, where it's main objectives will evaluate: Safety and tolerability of VE800 in combination with Nivolumab Efficacy as measured by a total of overall response rate. The study will enroll approximately 111 patients with melanoma, patients with gastric/gastroesophageal junction (GEJ) adenocarcinoma, and patients with …

Phase

5.43 miles

Learn More »

A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1 dose escalation will determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of SNDX-5613 in patients with acute leukemia. Patients with R/R acute leukemia are to be enrolled agnostic of genetic mutation status. Patients will be enrolled in one of two dose-escalation arms: Arm A: …

Phase

5.43 miles

Learn More »

A Study of BDTX-189 an Orally Available Allosteric ErbB Inhibitor in Patients With Advanced Solid Tumors.

BDTX-189 is an irreversible, small molecular inhibitor that is highly selective versus wild-type EGFR and potent for cancer driver mutations of the ErbB family, including extracellular, transmembrane, and kinase domain allosteric mutations of HER2, as well as EGFR and HER2 exon 20 insertion mutations. These allosteric ErbB mutations are found …

Phase

5.43 miles

Learn More »

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

This is a multicenter, worldwide, open-label study of MK-8353 in combination with selumetinib in participants with histologically or cytologically confirmed diagnosis of advanced solid tumor. This study will evaluate the safety, tolerability, and preliminary efficacy of MK-8353 in combination with selumetinib.

Phase

5.43 miles

Learn More »

A Study of XmAb 23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 in subjects with selected advanced solid tumors.

Phase

5.43 miles

Learn More »

Avelumab Program Rollover Study

The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.

Phase

5.43 miles

Learn More »

A Multi-Center Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

The study is an open-label, dose escalation and expansion clinical trial of surufatinib orally once daily (QD) in patients with advanced solid tumors. The study consists of two phases: Dose escalation phase - A 3+3 design will be used for this portion of the study. Approximately 15 to 35 evaluable …

Phase

5.43 miles

Learn More »